Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived antibody that specifically targets the CD20 antigen in monkeys and humans and exerts an inhibitory effect. It achieves selective depletion of B cells through its targeting action and is commonly used in research on inflammatory and metabolic diseases such as diabetes and experimental autoimmune encephalomyelitis (EAE).

In human CD20 transgenic NOD mouse models, intravenous administration of Anti-Monkey/Human CD20 Antibody (2H7) at a dose of 0.25–0.5 mg/kg, given once every 3 days for a total of 4 doses within 9 days, effectively depletes B cells and delays the progression of non‑obese diabetes [1].
In human CD20 transgenic C57BL/6 mice, intraperitoneal injection ofAnti-Monkey/Human CD20 Antibody (2H7) at a dose of 200 μg once weekly can prevent or reverse experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein [2].

2H7

Human/Monkey

Monoclonal

Unconjugated